Loading…

Camurus ABCAMX.STCompetitor analysis, valuation and peers

Sweden · SEK·Health Care›Pharmaceuticals: Major

Swedish pharma company developing long-acting injectable drugs for opioid dependence and pain, using its FluidCrystal delivery technology.

≈ A specialty drug-delivery pharma like a smaller IndiviorMomentum leader 90
Mkt cap
$4.36B
US dollars, full cap
Free float
65%
of shares outstanding
$/day
$7.81M
20-day average traded
Fwd P/E
45.1×
forward earnings
ROIC−WACC
+96.6 pp
WACC 5.0%
Hurdle
-39 pp
Req g minus delivered
Next earnings
92 days
18 Feb 2027
Close · SEKSEK 732.50
1D+0.4%
1W-0.6%
1M+10.3%
3M+17.3%
6M+36.0%
YTD+18.9%
1Y+13.8%
ATR %2.6%
52w lowhigh2.3% off high

What Camurus does

Swedish pharma company developing long-acting injectable drugs for opioid dependence and pain, using its FluidCrystal delivery technology.

Sells a weekly or monthly buprenorphine injection, marketed as Buvidal in Europe and Australia and as Brixadi in the US, for opioid dependence. It also earns milestone and licence payments when other drug makers use its FluidCrystal delivery technology for their own products.

In one line: A specialty drug-delivery pharma like a smaller Indivior.

Products and services

  • Brixadi (buprenorphine depot injection)
  • FluidCrystal drug-delivery technology
  • Pain-management pipeline

Customers

  • Addiction treatment providers
  • Hospitals
  • Licensing partners

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Long-acting injectable drug…

What could go right

  • Brixadi US/international sales growth
  • New indications for FluidCrystal platform

What could go wrong

  • Reimbursement/formulary access risk
  • Competition from generic buprenorphine

Moat: narrow (IP / patents, process know-how). Proprietary lipid-based depot delivery technology and patents on approved long-acting injectables.

Headquarters: Lund, Sweden · Founded: 1993 · Employees: 285

Named competitors

  • Indivior private or unlisted
  • Alkermes ALKS
  • Braeburn (private) private or unlisted
  • Orexo private or unlisted
  • Ipsen IPN.PA
  • Crinetics Pharmaceuticals CRNX
  • Novartis NOVN.SW

Camurus at a glance

Size Camurus (CAMX.ST) is a Sweden Health Care company (Pharmaceuticals: Major) with a market value of $4.36B, the 50th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 732.50 on 18 Nov 2026.

Performance Over six months the shares gained 36.0%, against +0.8% for the median peer and +2.8% for the Sweden market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue grew 3.0% over the last twelve months (peer median +10.2%); the operating margin is 38.4% (peer median 15.7%).

Valuation It trades at 45.1× forward earnings against a peer median of 29.9× (most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +46%, so the hurdle is -39 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 96.6 points above its cost of capital (5.0% WACC).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026CAMX.ST 140Peer median 103
Six months, rebased to 100: Camurus against the median of its 20 peers (local-currency closes).

Camurus financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueSEK 2.42BSEK 2.27BSEK 1.87BSEK 1.72BSEK 956M
Revenue growth—+21%+9%+80%—
Gross profitSEK 2.23BSEK 2.10BSEK 1.74BSEK 1.59BSEK 850M
EBITDASEK 958MSEK 907MSEK 484MSEK 544MSEK 83.5M
Net incomeSEK 756MSEK 736MSEK 428MSEK 431MSEK 55.6M
Free cash flowSEK 810MSEK 731MSEK 360MSEK 598MSEK 99.3M
Capital expenditureSEK 167MSEK 139MSEK 29.4MSEK 10.1MSEK 1.91M
Total debtSEK 107MSEK 106MSEK 17.0MSEK 24.5MSEK 26.2M

Quarterly statements and history in the cockpit →

Camurus competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-25%0%+25%600566AJANTPHARM002294600332IONS4536000100EMCUREDFTXGLAXO128940TVTXERAS600085688336IPCALAB326030CAMX.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Camurus is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%20×30×40×600566AJANTPHARM002294600332000100EMCUREGLAXOTVTX600079600085688336IPCALABPTCT326030CAMX.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Camurus is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%+100%0%50%100%600566AJANTPHARM0022946003324536EMCUREGLAXOTVTX301569600079688336PTCT326030CAMX.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Camurus is the large dot.

Camurus competitors and peer comparison

Head to head with its named competitors (CAMX.ST vs ALKS vs IPN.PA vs CRNX)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Camurus CAMX.ST$4.36B+36%+3%38%45.1×7.9%
Alkermes Public ALKS$7.87B+27%+15%5%n/a32.5%
Ipsen IPN.PA$14.8B+1%+14%30%10.8×-6.7%
Crinetics Pharmaceuticals CRNXn/a+109%n/an/an/an/a
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%

How Camurus compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Camurus against its 20 peers (data as of 18 Nov 2026)
MeasureCAMX.STPeer medianRank in peer set
1-month return+10.3%-2.9%6th highest of 21
6-month return+36.0%+0.8%3rd highest of 20
Distance from 52-week high-2.3%-32.7%2nd highest of 21
Revenue growth (TTM)+3.0%+10.2%8th lowest of 19
Operating margin38.4%15.7%2nd highest of 19
Forward P/E45.1×29.9×most expensive of 17
Growth the price implies (Req g, 7 yrs)7.9%5.7%8th most demanding of 17
Growth delivered (Del g)+46.5%+8.6%2nd highest of 17
Hurdle (Req g minus delivered)-38.5 pp-3.7 pp3rd least demanding of 17
ROIC minus cost of capital+96.6 pp+4.9 pphighest of 18
EV / EBITDA41.9×21.5×2nd most expensive of 11
Net debt / EBITDA-4.4×-0.5×3rd least indebted of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Camurus CAMX.STSweden$4.36B+36%+3%38%45.1×7.9%+46.5%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%16.2×-9.9%+0.3%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%31.7×23.8%+13.8%
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%35.4×12.4%+9.7%
Guangzhou Baiyunshan Pharmaceutical 600332.SSChina$4.45B-13%+1%3%12.9×-0.7%+4.7%
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%n/an/an/a
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%16.7×-5.0%+3.2%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%33.6×15.9%+12.7%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%37.3×26.4%+5.5%
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%17.1×17.3%+19.9%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%13.8×-8.8%+3.0%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%28.7×1.7%+6.2%
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%31.1×16.5%+12.2%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%31.2×6.6%+35.4%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%21.5×-4.4%+93.6%

Questions

Who are Camurus's main competitors?
Named competitors: Indivior (private or unlisted), Alkermes (ALKS), Braeburn (private) (private or unlisted), Orexo (private or unlisted), Ipsen (IPN.PA), Crinetics Pharmaceuticals (CRNX). The cockpit's measured peer set (industry) also includes HUBEI JUMPCAN PHARMACEUTICAL (600566.SS), Ajanta Pharma (AJANTPHARM.NS), Shenzhen Salubris Pharmaceuticals (002294.SZ), Guangzhou Baiyunshan Pharmaceutical (600332.SS), Ionis Pharmaceuticals (IONS), Santen Pharmaceutical (4536.T).
Is Camurus expensive compared with its peers?
On forward p/e it trades at 45.1× against a peer median of 29.9×, most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is +46%, so the hurdle is -39 pp: the price already allows for a slowdown.
How has Camurus stock performed?
Over six months to 18 Nov 2026 the shares returned +36.0% against +0.8% for the median peer; over one year +13.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.